An analyst downgrade and a departing executive make for a bad day.
News & Analysis: Seattle Genetics
Data from a pair of clinical trials sent shares of the oncology drugmaker higher.
Unfortunately, there were more of the latter.
Solid data for two pipeline candidates increases investors' confidence in the cancer biotech.
There's potential for more with a pipeline of drugs in development.
Despite declines in the broader market, good news lifted shares of these companies.
Sales growth of the biotech's blood cancer drug Adcetris rebounded.
SGEN earnings call for the period ending June 30, 2019.
The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.
SGEN earnings call for the period ending March 31, 2019.